Dynavax rises in morning trading

|About: Dynavax Technologies Corpor... (DVAX)|By:, SA News Editor

Dynavax Technologies (DVAX +8.4%) posts solid gains in morning trading.

The company said Tuesday evening that immunogenicity and safety results from two Phase 3 Heplisav trials were published in Vaccine along with some commentary by two doctors.

Long story short, here's what was said: These two trials are further evidence that the adjuvant in Heplisav is "important" in hepatitis B immunization. (PR)